Cover Image
市場調查報告書

胰島素的歐洲市場:2015年∼2019年

Insulin Market in Europe 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 336532
出版日期 內容資訊 英文 80 Pages
訂單完成後即時交付
價格
Back to Top
胰島素的歐洲市場:2015年∼2019年 Insulin Market in Europe 2015-2019
出版日期: 2015年07月29日 內容資訊: 英文 80 Pages
簡介

歐洲的胰島素市場預測從2014年到2019年間將以6.50%的年複合成長率擴大。該地區中糖尿病患者數的增加,是該成長的背景。

本報告提供歐洲的胰島素市場規模與今後的預測,提供您市場成長要素與課題,主要趨勢,主要供應商分析等資訊。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 產品簡介

  • Humalog
  • Liprolog
  • Actrapid
  • Levemir
  • NovoMix
  • NovoRapid
  • Tresiba
  • Apidra
  • Insuman
  • Lantus
  • Toujeo

第5章 市場調查手法

  • 市場調查流程
  • 調查手法

第6章 簡介

第7章 胰島素概要

  • 產品的組合
  • 流行病學
  • 開發平台的組合

第8章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第9章 各類型的市場分類

  • 速效型胰島素
    • 速效型胰島素
    • 正常人體胰島素
  • 中間型胰島素
    • NPH胰島素注射液
    • 混合型胰島素
  • 持久性功效型胰島素

第10章 購買標準

第11章 市場成長因素

第12章 成長因素與其影響

第13章 市場課題

第14章 成長因素與課題的影響

第15章 市場趨勢

第16章 趨勢與其影響

第17章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
    • Novo Nordisk
    • Sanofi
    • Eli Lilly
  • 其他卓越供應商

第18章 主要供應商分析

  • Eli Lilly
  • Novo Nordisk
  • Sanofi

第19章 相關報告

目錄
Product Code: IRTNTR6809

About insulin

Insulin is a hormone produced by the beta cells of the pancreas; insulin has a key role in regulating the blood glucose levels. It regulates the metabolism of glucose and other nutrients in the body. Insulin permits the body to utilize sugar (glucose) from carbohydrates in the food for energy or to store glucose for future use. The beta cells of the pancreas of people with type 1 diabetes do not produce sufficient insulin to regulate blood glucose level; therefore, they need to intake insulin daily. On the other hand, people with type 2 diabetes or gestational diabetes need doses of insulin together with other medication. Different type of insulin such as human insulin and insulin analogs are available for insulin replacement therapy.

Technavio's analysts forecast the insulin market in Europe to grow at a CAGR of 6.50% over the period 2014-2019.

Covered in this report

The report covers the present scenario and the growth prospects of the insulin market in Europe for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of various insulin used for the treatment of diabetes.

Technavio's report, Insulin Market in Europe 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the insulin market in Europe and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key vendors

  • Elli Lilly
  • Novo Nordisk
  • Sanofi

Other Prominent Vendors

  • Biodel
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Diamyd Medical
  • DiaVacs
  • Generex Biotechnology
  • Lexicon Pharmaceuticals
  • Macrogenics
  • Merck
  • Osiris Therapeutics
  • Pfizer
  • Tolerion
  • XOMA

Key market driver

  • Increase in prevalence of diabetes
  • For a full, detailed list, view our report

Key market challenge

  • Stringent regulatory environment
  • For a full, detailed list, view our report

Key market trend

  • Rise in awareness programs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

  • 04.1. Humalog
  • 04.2. Liprolog
  • 04.3. Actrapid
  • 04.4. Levemir
  • 04.5. NovoMix
  • 04.6. NovoRapid
  • 04.7. Tresiba
  • 04.8. Apidra
  • 04.9. Insuman
  • 04.10. Lantus
  • 04.11. Toujeo

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Insulin: An Overview

  • 07.1. Product Portfolio
  • 07.2. Epidemiology
  • 07.3. Pipeline Portfolio

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. Five Forces Analysis

09. Market Segmentation by Type

  • 09.1. Fast-acting Insulin
    • 09.1.1. Rapid-acting Insulin
    • 09.1.2. Regular Human Insulin
  • 09.2. Intermediate-acting Insulin
    • 09.2.1. NPH Human Insulin
    • 09.2.2. Pre-mixed Insulin
  • 09.3. Long-acting Insulin

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and Their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and Their Impact

17. Vendor Landscape

  • 17.1. Competitive Scenario
    • 17.1.1. Key News
    • 17.1.2. Mergers and Acquisitions
  • 17.2. Market Share Analysis 2014
    • 17.2.1. Novo Nordisk
    • 17.2.2. Sanofi
    • 17.2.3. Eli Lilly
  • 17.3. Other Prominent Vendors

18. Key Vendor Analysis

  • 18.1. Eli Lilly
    • 18.1.1. Key Facts
    • 18.1.2. Business Overview
    • 18.1.3. Business Segmentation by Revenue
    • 18.1.4. Sales by Geography
    • 18.1.5. Business Strategy
    • 18.1.6. Key Information
    • 18.1.7. SWOT Analysis
  • 18.2. Novo Nordisk
    • 18.2.1. Key Facts
    • 18.2.2. Business Overview
    • 18.2.3. Business Segmentation by Revenue 2013
    • 18.2.4. Business Segmentation by Revenue 2012 and 2013
    • 18.2.5. Sales by Geography
    • 18.2.6. Business Strategy
    • 18.2.7. Key Information
    • 18.2.8. SWOT Analysis
    • 18.2.9. Strengths
    • 18.2.10. Weakness
    • 18.2.11. Opportunities
    • 18.2.12. Threats
  • 18.3. Sanofi
    • 18.3.1. Key Facts
    • 18.3.2. Business Description
    • 18.3.3. Business Segmentation
    • 18.3.4. Revenue by Business Segmentation
    • 18.3.5. Revenue Comparison 2012 and 2013
    • 18.3.6. Sales by Geography
    • 18.3.7. Business Strategy
    • 18.3.8. Key Developments
    • 18.3.9. SWOT Analysis

19. Other Reports in This Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Number of People Aged 20-79 with Diabetes in Europe 2013 and 2035 (millions)
  • Exhibit 3: Percentage of People Aged 20-79 with Diabetes in Europe 2013 and 2035
  • Exhibit 4: Percentage of Undiagnosed People Aged 20-79 with Diabetes in Europe by Income 2013
  • Exhibit 5: Top Four Countries in Europe with High Proportion of Diabetic People 2013 (millions)
  • Exhibit 6: Few Countries in Europe with High Proportion of Diabetic People Aged 20-79 by Gender 2014
  • Exhibit 7: Insulin Market in Europe 2014-2019 ($ millions)
  • Exhibit 8: Segmentation of Insulin Market in Europe by Type
  • Exhibit 9: Major Drivers of Insulin Market in Europe
  • Exhibit 10: Percentage of People with Diabetes in 28 Member Countries in EU by Age Group 2013-2040
  • Exhibit 11: Percentage of People with Diabetes in Few European Countries by Age Group 2014
  • Exhibit 12: Factors Influencing Development of Insulin Delivery Devices
  • Exhibit 13: Diabetes Rule of Halves
  • Exhibit 14: Number of Diabetes and Undiagnosed Diabetes Cases in Few European Countries Among People Aged 20-79 2014
  • Exhibit 15: Ranking of Top Vendors
  • Exhibit 16: Novo Nordisk: Revenue of Insulin Products in Europe 2011-2014 ($ millions)
  • Exhibit 17: Novo Nordisk: YoY Growth and Revenue of NovoRapid in Europe 2011-2014 ($ millions)
  • Exhibit 18: Novo Nordisk: YoY Growth and Revenue of NovoMix in Europe 2011-2014 ($ millions)
  • Exhibit 19: Novo Nordisk: YoY Growth and Revenue of Levemir in Europe 2011-2014 ($ millions)
  • Exhibit 20: Novo Nordisk: YoY Growth and Revenue of Human Insulins in Europe 2011-2014 ($ millions)
  • Exhibit 21: Sanofi: YoY Growth and Revenue of Lantus in Western Europe 2011-2014 ($ millions)
  • Exhibit 22: Sanofi: YoY Growth and Revenue of Apidra in Western Europe 2011-2014 ($ millions)
  • Exhibit 23: Sanofi: YoY Growth and Revenue of Insuman in Western Europe 2011-2014 ($ millions)
  • Exhibit 24: Eli Lilly: Business Segmentation by Revenue 2013
  • Exhibit 25: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 ($ millions)
  • Exhibit 26: Eli Lilly: Sales by Geography 2013
  • Exhibit 27: Novo Nordisk: Business Segmentation by Revenue 2013
  • Exhibit 28: Novo Nordisk: Business Segmentation by Revenue 2012 and 2013 ($ billions)
  • Exhibit 29: Novo Nordisk: Sales by Geography 2013
  • Exhibit 30: Sanofi: Business Segmentation
  • Exhibit 31: Sanofi: Revenue by Business Segmentation 2013
  • Exhibit 32: Sanofi: Revenue by Business Segmentation 2012 and 2013 ($ millions)
  • Exhibit 33: Sanofi: Sales Revenue by Geographical Segmentation 2013
Back to Top